About Spidia
SPIDIA is a 4-year project, funded by the European Union FP7 programme to the value of 9 million Euros, which brings together a consortium of 16 leading academic institutions, international organisations and life sciences companies.
The project is coordinated by QIAGEN GmbH and aims to tackle the standardisation and improvement of pre-analytical procedures for in-vitro diagnostics. The proposed research and standardisation activities cover all steps from creation of evidence-based guidelines to creation of tools for the pre-analytical phase to testing and optimisation of these tools through the development of novel assays and biomarkers.
+++ LATEST NEWS +++ LATEST NEWS +++ LATEST NEWS +++ LATEST NEWS +++ LATEST NEWS +++
SPIDIA Ring Trials
The second run of the three SPIDIA Ring Trials with the following three categories: Blood-derived DNA, cell-free DNA from plasma, and blood-derived RNA, is starting in early 2012.
Click here to see examples of results reports you will receive later on for your samples (depending on the chose ring trial): DNA, DNAplas, RNA, and visit http://www.efcclm.eu/spidia/, where you can find more information.
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Read our most recent NEWSLETTER including important information about SPIDIA's project progress!
SPIDIA Newsletter 10 2011
+++ LATEST NEWS +++ LATEST NEWS +++ LATEST NEWS +++ LATEST NEWS +++ LATEST NEWS +++
This work is supported by funding under the Seventh Research Framework Programme of the European Union, (FP7-HEALTH-2007-1.2.5). This website has been created in the context of the SPIDIA project. All information is provided "as is" and no guarantee or warranty is given that the information fits for any particular purpose. The user thereof uses the information at its sole risk and liability.
